Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer.

doi:10.1158/1078-0432.CCR-23-3403

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 3 Sept 2024

Lenis Andrew T, Ravichandran Vignesh, Brown Samantha, Alam Syed M, Katims Andrew, Truong Hong, Reisz Peter A, Vasselman Samantha, Nweji Barbara, Autio Karen A, Morris Michael J, Slovin Susan F, Rathkopf Dana, Danila Daniel, Woo Sungmin, Vargas Hebert A, Laudone Vincent P, Ehdaie Behfar, Reuter Victor, Arcila Maria, Berger Michael F, Viale Agnes, Scher Howard I, Schultz Nikolaus, Gopalan Anuradha, Donoghue Mark T A, Ostrovnaya Irina, Stopsack Konrad H, Solit David B, Abida Wassim

Abstract excerpt

PURPOSE: Patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) and high tumor mutational burden (TMB-H) prostate cancers are candidates for pembrolizumab. We define the genomic features, clinical course, and response to immune checkpoint blockade (ICB) in patients with MSI-H/dMMR and TMB-H prostate cancers without MSI [TMB-H/microsatellite stable (MSS)]. EXPERIMENTAL DESIGN: We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Antibodies, Monoclonal, Humanized

Share to Biomarkers, Tumor

Share to DNA Mismatch Repair

Share to Immune Checkpoint Inhibitors

Share to Microsatellite Instability

Share to Prostatic Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 38949888
DOI: 10.1158/1078-0432.CCR-23-3403
PMCID: PMC11371520

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer.PMID 38949888Read ↗

Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

Microsatellite instability in prostate cancer by PCR or next-generation sequencingSemantic proximity Read ↗

Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA.Semantic proximity Read ↗

Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies.Semantic proximity Read ↗

A Real-World Experience of Pembrolizumab Monotherapy in Microsatellite Instability-High and/or Tumor Mutation Burden-High Metastatic Castration-Resistant Prostate Cancer: Outcome AnalysisSemantic proximity Read ↗

Clinical Implications of Mismatch Repair Deficiency in Prostate CancerSemantic proximity Read ↗

Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.Semantic proximity Read ↗

Comprehensive Analysis of Tumor Mutational Burden in Prostate Cancer: Multipublic Dataset Analysis.Semantic proximity Read ↗

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.Semantic proximity Read ↗

Prevalence of mismatch repair genes mutations and clinical activity of PD-1 therapy in Chinese prostate cancer patientsSemantic proximity Read ↗

Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancersSemantic proximity Read ↗

Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair DefectsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.